logo
  

Performance Food Group Guides Q4 Net Sales Below View; Trims FY24 Net Sales Outlook - Update

While reporting financial results for the third quarter on Wednesday, Performance Food Group Co. (PFGC) provided net sales guidance for the fourth quarter, below estimates. The company also trimmed its net sales guidance for the full-year 2024.

For the fourth quarter, PFG expects net sales in a range of $15.0 billion to $15.4 billion. On average, 11 analysts polled by Thomson Reuters expect the company to report revenues of $15.60 billion for the quarter.

Looking ahead to fiscal 2024, PFG now projects net sales in a range of about $58.1 billion to $58.5 billion, down from the prior expectation of a $59 billion to $60 billion range. The Street is looking for net sales of $59.02 billion for the year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast. Shares of Marks and Spencer Group Plc or M&S were gaining more than 7 percent in the morning trading in London after the retail major reported Wednesday significantly higher profit and sales in its fiscal 2024. The company also announced a dividend, and said it is confident to make further progress in 2025 and beyond.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT